Phase I trial of ALN-HTT, an RNAi drug-device combination product, for the treatment of Huntington's disease.
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2012
At a glance
- Drugs ALN HTT (Primary)
- Indications Huntington's disease
- Focus Pharmacodynamics; Therapeutic Use
- 02 Mar 2012 New trial record